Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.88 and traded as high as $6.80. Achieve Life Sciences shares last traded at $6.67, with a volume of 891,091 shares traded.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on ACHV. UBS Group reissued a "buy" rating on shares of Achieve Life Sciences in a research note on Tuesday, June 23rd. Canaccord Genuity Group set a $13.00 price target on Achieve Life Sciences and gave the company a "buy" rating in a research note on Monday, April 20th. Wall Street Zen upgraded Achieve Life Sciences from a "sell" rating to a "hold" rating in a report on Sunday, May 17th. Weiss Ratings upgraded Achieve Life Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 22nd. Finally, Raymond James Financial started coverage on Achieve Life Sciences in a research report on Friday, June 26th. They issued a "strong-buy" rating and a $20.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Achieve Life Sciences has an average rating of "Buy" and a consensus price target of $16.00.
Check Out Our Latest Analysis on Achieve Life Sciences
Achieve Life Sciences Price Performance
The company's fifty day moving average is $5.96 and its two-hundred day moving average is $4.88. The firm has a market capitalization of $684.74 million, a price-to-earnings ratio of -5.96 and a beta of 2.24. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.87.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.11. Equities research analysts anticipate that Achieve Life Sciences, Inc. will post -0.81 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in ACHV. 683 Capital Management LLC bought a new position in Achieve Life Sciences during the fourth quarter worth about $1,068,000. Manchester Financial Inc. grew its position in shares of Achieve Life Sciences by 26.6% during the 4th quarter. Manchester Financial Inc. now owns 59,084 shares of the biopharmaceutical company's stock worth $294,000 after buying an additional 12,410 shares during the period. Jefferies Financial Group Inc. bought a new stake in shares of Achieve Life Sciences in the 4th quarter valued at about $84,000. Robertson Stephens Wealth Management LLC increased its stake in shares of Achieve Life Sciences by 100.0% in the 4th quarter. Robertson Stephens Wealth Management LLC now owns 20,000 shares of the biopharmaceutical company's stock valued at $99,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Members Wealth LLC acquired a new stake in shares of Achieve Life Sciences in the 4th quarter valued at approximately $153,000. 33.52% of the stock is currently owned by institutional investors.
Achieve Life Sciences Company Profile
(
Get Free Report)
Achieve Life Sciences, Inc NASDAQ: ACHV is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.
Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
